Loading patent…
AssigneeCouncil of Scientific and Industrial Research
InventorsSanju Dhawan, Anil Kumar Singla
Estimating the term…
A composition useful for reducing serum glucose levels by an oral controlled release system and a method for treating diabetes in a human being by controlling the blood glucose level (BGL) and reducing the complications associated with diabetic hyperglycemia and also the long term management of Non-Insulin Dependent Diabetes Mellitus (NIDDM) by avoiding the problems associated with the tight control of BGL, i.e., hypoglycemia tolerance and seizures. The composition is directed to a solid, hydrophilic matrix controlled release oral dosage form where the dosage form contains a therapeutically effective amount of antidiabetic drug in the matrix ensuring complete bioavailability of the drug from the matrix of the tablet. The formulation undergoes substantially or approaches zero order release of active drug and the concentration of the excepients and the water swellable polymers is chosen in such a way that the erosion or dissolution rate of the polymer is equal to the swelling rate of the polymer to get a constant release. Also, the concentration is chosen in such a way that the tablet will be fully dissolved at the same time the last of the drug is released and in addition a bioadhesive polymer may also be added to increase the residence time of the dosage form in the g.i.t. and at high concentration of the polymer, beta cyclodextrin may also be added to improve the release kinetics.
A composition for reducing serum glucose levels having an oral controlled release system, comprising:
A composition as recited in 1, wherein the said polymer is hydrophilic and water swellable.
A composition for reducing serum glucose levels by an oral controlled release system, comprising polyethylene oxide 10-40% by weight, drug 5-10%, and pharmaceutically acceptable additive 0 to 5% and dicalcium Phosphate q.s.
A once a day controlled release tablet for reducing serum glucose level and for treating hyperglycemia, comprising:
A method of reducing a patient's serum glucose level, comprising:
A method for treating hyperglycemia in a patient, wherein the method comprises administering to the patient a dosage form comprising 2 mg to 50 mg glipizide, which is administered at a therapeutical dose effective over 24 hours from the dosage form comprising one or more hydrogel selected from the group consisting of poly(ethylene oxide) having a 4,000,000 to 8,000,000 molecular weight and a hydroxy propylmethylcellulose (viscosity 4,000 to 21,000 cps ) and carboxypolymethylene (carbopol 934P) to the patient to produce the intended effect.
A process for producing a pharmaceutical composition used for treating mammals, said process comprising preparing a core made of medicament and optionally with one or more pharmaceutically acceptable additives, which core is encapsulated or made into a matrix with water soluble, high viscosity, bioadhesieve polymer.
Dependencies are inferred from the claim text.